Literature DB >> 8540312

The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer.

K Miki1, M Ichinose, N Kakei, N Yahagi, M Matsushima, S Tsukada, S Ishihama, Y Shimizu, T Suzuki, K Kurokawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8540312     DOI： 10.1007/978-1-4615-1871-6_17

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  21 in total

1.  Analysis of ABC (D) stratification for screening patients with gastric cancer.

Authors:  Tomohiro Kudo; Satoru Kakizaki; Naondo Sohara; Yasuhiro Onozato; Shinichi Okamura; Yoshikatsu Inui; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

2.  Strategy for eliminating gastric cancer in Japan.

Authors:  Masahiro Asaka; Mototsugu Kato; David Y Graham
Journal:  Helicobacter       Date:  2010-12       Impact factor: 5.753

3.  Gastric cancer screening using the serum pepsinogen test method.

Authors:  Kazumasa Miki
Journal:  Gastric Cancer       Date:  2006-11-24       Impact factor: 7.370

4.  Randomized controlled trial comparing gastric cancer screening by gastrointestinal X-ray with serology for Helicobacter pylori and pepsinogens followed by gastrointestinal endoscopy.

Authors:  Takuji Gotoda; Hideki Ishikawa; Hirohide Ohnishi; Kentaro Sugano; Chika Kusano; Chizu Yokoi; Yutaka Matsuyama; Fuminori Moriyasu
Journal:  Gastric Cancer       Date:  2014-08-13       Impact factor: 7.370

5.  Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study.

Authors:  H Watabe; T Mitsushima; Y Yamaji; M Okamoto; R Wada; T Kokubo; H Doi; H Yoshida; T Kawabe; M Omata
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

6.  Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis.

Authors:  Shigeto Mizuno; Ikuya Miki; Tsukasa Ishida; Masaru Yoshida; Mitsuko Onoyama; Takeshi Azuma; Yasuki Habu; Hideto Inokuchi; Kotaro Ozasa; Kazumasa Miki; Yoshiyuki Watanabe
Journal:  Dig Dis Sci       Date:  2010-03-04       Impact factor: 3.199

7.  The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk.

Authors:  Mitsuru Kaise; Jun Miwa; Jun Tashiro; Yasukazu Ohmoto; Shingo Morimoto; Masayuki Kato; Mitsuyoshi Urashima; Masahiro Ikegami; Hisao Tajiri
Journal:  J Gastroenterol       Date:  2011-04-01       Impact factor: 7.527

8.  Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects.

Authors:  Y Yamaji; T Mitsushima; H Ikuma; M Okamoto; H Yoshida; T Kawabe; Y Shiratori; K Saito; K Yokouchi; M Omata
Journal:  Gut       Date:  2001-09       Impact factor: 23.059

9.  Influence of Helicobacter pylori status and eradication on the serum levels of trefoil factors and pepsinogen test: serum trefoil factor 3 is a stable biomarker.

Authors:  Mitsuru Kaise; Jun Miwa; Ai Fujimoto; Jun Tashiro; Daisuke Tagami; Hiromi Sano; Yasukazu Ohmoto
Journal:  Gastric Cancer       Date:  2012-08-21       Impact factor: 7.370

10.  Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics.

Authors:  N Broutet; M Plebani; C Sakarovitch; P Sipponen; F Mégraud
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.